How to select a presumably normal population for the establishment of 99th percentile cutoffs for cardiac troponin assays has not been adequately addressed. Lack of attention to this question can result in misleading medical decision cutoffs.
The Global Task Force for the Third Universal Definition of Myocardial Infarction has advocated using the cardiac troponin I (cTnI) 5 or cTnT 99th percentile of a normal, healthy reference population [upper reference limit (URL)] as the decision level for the diagnosis of myocardial infarction (MI) (1 ) . The consensus document remarks how the value for the 99th percentile URL can be identified either in package inserts from the assay manufacturer or in peer-reviewed publications. Studies have been performed for many cardiac troponin assays in the marketplace to define the URL. However, an important overlooked topic remains: how do studies define a "normal" individual for enrollment into a reference study? To date, there have been no clear guidelines on what defines normality to establish the "correct" 99th percentile value (2) (3) (4) (5) (6) . Getting the 99th percentile value correct for high-sensitivity (hs) cardiac troponin assays is especially important for appropriate classification of MI in routine patient care and for clinical studies involving MI adjudication, as well as for prognostic assessment of patients presenting to emergency rooms with acute coronary syndrome and nonischemic events. Additionally, in the future cardiac troponin may have utility in primary prevention. Our purpose is to propose a starting point for development of the criteria to be used in studies to qualify individuals as presumably healthy or normal. Our viewpoint is based on review of published studies designed to determine the 99th percentile of cTnI and cTnT assays.
Standardizing the process to define normality would harmonize the ability to compare assays across studies and facilitate research efforts, as well as aid with the challenges manufacturers have during the development of new cardiac troponin assays and US Food and Drug Administration (FDA) clearance (2, 4, (7) (8) .
What definition of normality is to be used, during the current transition in which hs-cardiac troponin assays are approaching clinical implementation in the US (likely in 2014), is fundamentally important given the role and implications cardiac troponin plays in diagnostics, therapeutics, and prognosis. hs Cardiac troponin assays are already Conformité Européenne marked for use outside the US. Here lies the importance of reviewing the global status with regard to normal reference studies.
Defining Normality
The CLSI document Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory (EP28-A3c) provides guidance for determining laboratory test reference intervals (9 ) . However, the real-world pro-cess leading to the selection of "normal" subjects across different studies is highly variable, ranging from a failure to supply a detailed definition of how normal subjects were selected (10 -16 ) , to primarily using health questionnaires or reviewing baseline clinical characteristics (17) (18) (19) (20) (21) (22) (23) (24) , to more selective screening methods using surrogate blood biomarkers, electrocardiography, imaging, and/or physical examination in addition to assessment of known baseline clinical variables (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . Several studies have relied exclusively on questionnaires to define reference individuals. Assessments of known clinical variables are often limited to reporting only a history of cardiovascular disease (18, 35 ) or may involve more extensive screening for multiple variables, including known morbidities and current medications (19 -20 ) . Some studies have used highly selective screening methods to define the final reference population. Two model studies were designed as follows. In the first study, Collinson et al. tested the influence of population selection on the 99th percentile URL, assessing multiple variables including known baseline clinical characteristics, surrogate blood biomarkers [i.e., fasting plasma glucose (diabetes), creatinine (renal function), N-terminal prohormone of brain natriuretic peptide (NT-pro BNP) (myocardial dysfunction)] as well as electrocardiogram, echocardiography, and spirometry (32 ) . The study assessed the variability on the 99th percentile among 3 assays: cTnI Siemens Ultra, hs-cTnT Roche, and Accu cTnI Beckman Coulter. A substantial decrease in the 99th percentile was shown in 2 of the 3 assays studied, depending on how normality was defined. With the use of the "questionnaire plus NT-proBNP Ͻ250 ng/L" method, the 99th percentiles were 38.7 ng/L, 16.7 ng/L, and 67.2 ng/L, respectively, in comparison to 38.6 ng/L, 20.0 ng/L, and 66.4 ng/L when only the questionnaire was used as a screening method. NT-proBNP excluded 37.7% of the values, although it was mentioned that the use of an NT-proBNP cutoff of 100 ng/L resulted in a more effective filter. Most importantly, 99th percentiles were calculated as absolute, single, upper 99th percentile values. In the second study, McKie et al. (34 ) , using the Siemens Dimension Vista assay, defined hscTnI reference values in both community-based and healthy reference cohorts. Participants underwent clinical assessment and echocardiographic imaging evaluation, as well as surrogate biomarker screening. The investigators determined that age, male sex, blood pressure, and left ventricular mass contributed to higher cTnI concentrations. Unfortunately, this study did not define the statistical analysis method used to calculate their 99th percentile values.
Surrogate markers used to screen for a truly healthy population that deserve discussion in more detail include natriuretic peptides, renal function, and imaging results. NT-proBNP instead of BNP (owing to stability issues with the latter) has been used in several studies (27, (31) (32) 36 (31 ) .
Various imaging methods have been applied, including stress echocardiography (25, 28 ) and transthoracic echocardiograms to assess left ventricular ejection fraction (LVEF) and mass (29, (31) (32) 34 ) . For example, Tate et al. excluded 3 out of 111 individuals who had cardiovascular abnormalities with stress echocardiography (25 ) . Logic suggests that a reference population should be free from structural heart disease, as determined by echocardiography, cardiac MRI, or computed tomography angiography (2, 4, 37 ) . However, a screening approach that included evaluation by a physician of potential reference study individuals, as well by an electrocardiogram and echocardiogram or a more sensitive MRI technique, would be expensive and realistically cost prohibitive (3 ) .
Renal function has been assessed frequently in potential reference study individuals (25, 28 -32 ) . For example, in the study by Collinson et al., the inclusion of estimated glomerular filtration rate (eGFR) of Ͼ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 after the initial questionnaire had the greatest effect on decreasing the 99th percentile for cTnT, but not for cTnI. The authors concluded that this finding was expected, because circulating cTnT is more sensitive to changes in eGFR (32 ) . Table 1 shows the wide range of variables that have been used in 99th percentile URL studies. No standard method for the selection of reference individuals for study participation has been followed across studies. Manufacturers' package inserts provide no consistency in the demographic make-up of reference populations or numbers of individuals enrolled to determine the 99th percentile (3 ). The FDA publicly provides no guidance. The most comprehensive 99th percentile study assessed a common set of results from presumably healthy individuals in 19 different cardiac tro-ponin assays (38 ) . In this study as well as in a smaller study (25 ) , differences in the determined 99th percentiles were observed for many assays when they were compared to the manufacturers' package insert 99th percentiles. Such findings would be expected with the assessment of nonuniformly defined normal groups of participants in the different studies. Representative of the variations observed, Table 2 shows a list of 99th percentiles according to the manufacturers' package inserts for hs-cardiac troponin assays (3 ), compared to 99th percentiles reported in selected research studies.
Sex and Age
Sex has been identified as an important factor in the selection of reference individuals. Several studies have shown differences in 99th percentiles among men and women, especially for hs cardiac troponin assays with the ability to measure cardiac troponin concentrations above the limit of detection (LoD) of the assay in Ͼ50% of normal study participants (Table 2 ). For hscardiac troponin assays, sex-specific 99th percentiles will need to be determined and reported for clinical use (2, 24, 34, 38 ) .
Few studies have reported 99th percentiles among different age groups. Venge et al. (26 ) , using an hscTnI prototype assay (Beckman-Coulter), found that the 99th percentile concentration was greater (0.019 g/L) in individuals Ͼ60 years old than in individuals Ͻ60 years old (0.010 g/L). McKie et al. (34 ) , also using an hs-cTnI assay (Siemens), showed an incremental increase of cTnI with increasing age for both men and women across 3 age groups, 45-54, 55-64, and Ն65 years. A 2-tiered approach has been suggested in which a group consisting of very young normal individuals (Ͻ30 years old) as well as an older group with presumably healthy individuals (Ͼ30 -70-plus years old), more representative of the ages of patients who present with symptoms suggestive of myocardial ischemia, be recruited to determine 99th percentile values (3 ). Whether age-by-decade-specific 99th percentile values will be necessary remains to be determined. The difficulty in recruiting healthy individuals over the age of 60 years in the US remains a challenge, and the biomarker cTnI itself is often the most sensitive tool to detect silent cardiac pathologies common in this age group. An interesting study in children by Koerbin et al. recently reported 99th percentiles of hs-cTnI (Abbott) in healthy children followed over several years, at ages 8,10, and 12 years (39 ). The 99th percentiles were 9.4, 10.5, and 10.2 ng/L, respectively, in boys and 8.2, 10.1, and 7.9 ng/L in girls. In comparison to adults using the same assay, 99th percentiles were 13.6 ng/L for all individuals, 14.0 ng/L in men, and 11.1 ng/L in women (40 ) . Further research will be required to assess the clinical significance or need to report separate 99th percentile values in healthy children/adolescents.
Ability to Measure Cardiac Troponin in Normal Individuals
Previously, a "scorecard" to classify cardiac troponin assays based upon analytical characteristics was proposed; different sensitivity levels were designated according to (a) the ability to obtain a measurable cardiac troponin value above the assay's LoD and (b) the imprecision (%CV) of an assay at the 99th percentile (41 (27 ) .
Serum, Plasma, or Whole Blood Cardiac Troponin
The CLSI/IFCC guidelines for reference value determination provide details from a laboratory perspective on how specimens should be collected (whole blood, plasma, or serum), handled, and stored (9 ) . Because 99th percentile values have been shown to vary by specimen type, it is important to clearly identify what specimen type was used in the methods section of a report (10, 14, 19, 25 ) . For example, Tate et al. studied the 99th percentile in both plasma and serum among several cardiac troponin assays, finding concordant values for the 2 specimen types across the majority of assays. Plasma and serum concentrations, respectively, were as The Global Need to Define Normality Other studies have shown similar findings. This is exemplified by the study of Apple et al., in which similar 99th percentiles in serum and plasma were found with the Access Accu cTnI (plasma and serum, 0.04 g/L) and VITROS I-ES cTnI (plasma, 0.031 g/L; serum, 0.034 g/L), whereas the ARCHITECT cTnI showed marked differences (plasma, 0.012 g/L; serum, 0.025 g/L) (10 ). We suggest that both the literature and the manufacturers' package inserts specify details according to specimen type to permit appropriate selection of 99th percentiles for use in clinical practice.
Statistics and Number of Reference Individuals
A nonparametric analysis method is recommended for establishing reference intervals (9, 32 ) and is the most common statistical method used in studies reporting a 99th percentile (10, 14 -15, 18 -20, 23, 27, 32, 36 ) . Review of the clinical and laboratory medicine literature demonstrates the poor quality of appropriate descriptions of statistical methods used to calculate the 99th percentile; some studies report what methods were used (10, 14 -15, 18 -19, 22, 27, 32, 35, 36, 38, 42 ) , whereas others do not (11-13, 16, 17, 21, 25, 26, 29, 30, 43 ) . The minimum number of reference individuals needed to appropriately determine the 99th percentile value for cardiac troponin has been reported to be 300, according to IFCC Task Force recommendations (3 ). In 2010, the European Society of Cardiology study group on biomarkers in cardiology (37 ) reported that a sample size of at least 300 individuals per group is required to reach a 95% probability that at least 99% of the population will fall below the highest observed cardiac troponin value (44 ) . This number is at variance with the CLSI/IFCC recommended population size of 120 reference individuals, which represents the minimum number of individuals necessary for the use of a nonparametric estimation method to estimate the limits of a central 95% reference interval with limits at the 2.5th and 97.5th percentiles (9 ) . This same CLSI/IFCC document emphasizes that when separate intervals are needed for different subclasses (i.e., sex or age), each subclass should also have a minimum of 120 reference individuals. In the most recent update (in December 2012) the IFCC WG-TNI (Working Group on the Standardization of Troponin I) (45 ) concurred that a sample size of at least 300 individuals per sex-and agematched reference population should avoid the effect of outliers and achieve a 95% probability that at least 99% of the population will have a cardiac troponin concentration representative of health. Therefore, 300 males and 300 females (600 total normal study participants) would be necessary to determine the 99th percentile value for each sex (3, 37 ) . Extending this criterion to establishing a 99th percentile for each subgroup by sex, age (by decade), and ethnicity/race would require a total of 1800 individuals for each ethnicity/race group, distributed across ages 20 through 70-plus years, with a 50%:50% male/female ratio. Besides sex, which is mandatory, a good representative mix of race/ ethnicity is more practical, including an approximate 40%:40% mix of whites and African Americans, with the remaining 20% a mix of Hispanic, Asian, and other racial/ethnic groups, similar to NIH suggestions.
The (38 ) , and other studies (17, 18, 20, 27 ) . However, no study to date has included a sufficient number of individuals in the normal reference population to determine the 99th percentile for both men and women.
Key Concepts and Recommendations
In our review of the peer-reviewed literature, including international recommendations, we found that no uniform procedure is followed and no uniform guideline has been published by experts or regulatory agencies to guide researchers or manufacturers of cardiac troponin assays in their quest to define normality. As we move globally into the era of hs cardiac troponin assays, such guidelines are needed. We propose that the following guidelines be considered as, at least, a starting point for discussion.
First, an expert consensus group consisting of laboratory and clinical scientists, along with biomedical statisticians and industry and regulatory representatives, should convene to develop a definitive path forward. Second, in the interim, the screening and enrollment of presumably normal individuals into a study of the hs cardiac troponin assay 99th percentile should be conducted in such a way as to minimally address the information outlined in Table 3 , including clinical history for known cardiovascular disease and medication usage; surrogate biomarkers for diabetes and myocar-dial and renal dysfunction; a minimum of 300 men and 300 women; appropriate, nonparametric statistical analysis; possible inclusion of an imaging modality if financially feasible; and description of specimen type used. These criteria should be applied to all cTnT and cTnI assays, whether they are contemporary, point of care, or hs. As noted, however, only hs assays require independent male and female 99th percentiles. Our third recommendation is that discussions be undertaken with the in vitro manufacturers that market cardiac troponin assays regarding the possibility of pooling their resources to assist in the appropriate funding of a study to determine the URL for currently marketed assays. A uniform approach to defining and selecting "normal" individuals in the reference population will go a long way toward the development of successful strategies for diagnostic and risk outcome assessments in the management of patients with suspected myocardial injury, for current clinical practice as well as for potential future use in primary prevention.
This review was not intended to include nor does it address the metric of a gold standard for MI; instead we addresses only the 99th percentile value metric. However, we are of the opinion that as hs assays capable of measuring 100% of normal individuals with an imprecision of Յ10% CV at the 99th percentile become available, the future metric may shift from the 99th percentile to the more conventional 97.5th percentile as used in laboratory medicine for most analytes. The ultimate proof of whether 99th percentile values derived according to sex and/or ethnicity will have clinical relevance will rest on the findings of the evidence-based literature of future studies. Clinical history for known cardiovascular disease and medication usage.
Surrogate biomarker for diabetes.
Hemoglobin A 1c .
Surrogate biomarker for myocardial dysfunction.
NT-proBNP.
Surrogate biomarker for renal dysfunction.
Creatinine for eGFR calculation.
Inclusion of an imaging modality if financially feasible.
Diverse population of sufficient sample size.
Minimum 300 men and 300 women.
Diversity of race/ethnicity with approximately 40% white, 40% African American, and 20% mix of Asian, Hispanic and other races/ethnicities.
Diverse distribution of ages from 18 to Ͼ70 years.
Appropriate statistical analysis.
Description of specimen type utilized.
Whole blood, serum, plasma.
The Global Need to Define Normality

Review
Clinical Chemistry 60:3 (2014) 461
